radiation dermatitis
Published 2 months ago • 60 plays • Length 20:06Download video MP4
Download video MP3
Similar videos
-
2:13
what percentage of patients are diagnosed in the general oncology setting and not referred? #aml
-
0:44
b7-h6/cd3 t-cell engager bi 765049 ± ezabenlimab in advanced solid tumors expressing b7-h6
-
0:38
acne, vessels, scar, redness, rosacea - cutera excelv
-
1:43
a worldwide phase iii trial treating aml with pracinostat
-
2:01
mir-371a-3p as a biomarker in testicular cancer
-
3:11
immunohistochemistry: tfe3
-
1:48:04
aml: better alternatives to 7 3 - for whom, how & why ?
-
5:04
set-up (3/14)
-
16:17
3mensio ct pre-case planning: tavr in bicuspid valve, part 1
-
17:20
3mensio ct pre-case planning: valve-in-valve tavr in perimount/magna surgical aortic valve (sav)
-
![probe-based 3d cle of brain tumors – supplementary materials 2 [id 165980]](https://i.ytimg.com/vi/TjQiF_j9K8w/mqdefault.jpg)
0:12
probe-based 3d cle of brain tumors – supplementary materials 2 [id 165980]
-
6:46
how can venetoclax combinations improve outcome for flt3-mutant aml?
-
1:15
montblanc: sequential or up-front durvalumab, tremelimumab, bevacizumab in unresectable hcc
-
0:54
where do adcs fit in the treatment landscape of urothelial carcinoma?
-
6:21
melanoma 2
-
1:49
the prognostic value of flt3-itd residual disease in aml
-
0:31
understanding abbe values in lenses | the optom's lab
-
1:28
assaying flt3 variant allele frequency in aml to determine response to treatment
-
0:33
there are two molecules with the formula c_3 h_6. propene, ch_3 …
-
3:03
b-cell maturation antigen (bcma) 2 1 t cell engager cc-93269 in patients with rr multiple myeloma
-
0:44
unmet needs in aml: tp53 mutations and maintenance therapy
-
1:06
targeting tcf3-hlf−positive all